Frits de Smet
Ghent University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Frits de Smet.
Fundamental & Clinical Pharmacology | 1989
Frans Belpaire; Frits de Smet; B. Chindavijak; Norbert Fraeyman; Marcus Bogaert
Summary— Plasma concentrations after oral administration of the high extraction drug propranolol are increased in patients and animals with inflammation. This could be due to increased serum propranolol binding, but also to decreased first‐pass metabolism. We studied the pharmacokinetics of 3 drugs in control rats and in rats with turpentine‐induced inflammation: propranolol, which is bound extensively to α1‐acid glycoprotein (α1‐AGP); metoprolol, another high extraction drug, but which is negligibly bound to α1‐AGP; and antipyrine, a low extraction drug, not bound to serum proteins.
Mechanisms of Ageing and Development | 1993
Frans Belpaire; M. T. Rosseel; An Vermeulen; Frits de Smet; Marc G. Bogaert
The pharmacokinetics of R- and S-atenolol after intravenous administration of racemic atenolol were studied in 3-, 12- and 24-month-old rats and in 3-month-old rats with renal failure induced by uranyl nitrate. In all age groups, the area under the plasma concentration-time curves is higher for R- than for S-atenolol; volume of distribution, total clearance and renal clearance are lower for R-atenolol than for S-atenolol, but the differences are small. In function of age there is for both enantiomers a significant increase in AUC, due, at least in part, to a decreased renal clearance; the effect of aging is not stereoselective. In rats with renal failure, the AUC of both enantiomers increases, due mainly to a decrease in renal clearance, but to a lesser degree also to a decrease in nonrenal clearance. For both enantiomers, the volume of distribution decreases and the half-life increases in the uraemic rats. The total amount of both enantiomers excreted in the urine is decreased in the rats with renal failure. There are no stereoselective effects of treatment of the rats with uranyl nitrate.
Journal of Pharmacy and Pharmacology | 1990
Frans Belpaire; André De Rick; Alain Bourda; Frits de Smet; M. T. Rosseel; Marc G. Bogaert
Abstract— The effect of lignocaine (lidocaine) on the plasma protein binding of verapamil has been studied in‐vitro and in‐vivo in dogs. The binding of verapamil was ca 85%. In‐vitro addition of lignocaine at therapeutic concentrations displaced verapamil from its plasma binding sites. Lignocaine in this regard was equipotent with tris(2‐butoxyethyl)phosphate, suggesting an interaction at the level of α1‐acid glycoprotein binding sites. On in‐vivo administration of 4 mg kg−1 in a bolus to dogs in which steady state concentrations of verapamil were present, the free fraction of verapamil increased transiently. During the lignocaine maintenance infusion, it then decreased to a level higher than that before administration of the local anaesthetic. The free verapamil concentrations increased suddenly upon the administration of the lignocaine loading dose, and then returned to values slightly higher than those before lignocaine. After a bolus injection of verapamil during a lignocaine infusion, the verapamil total plasma concentrations were lower than during a saline infusion, but the free concentrations were not different. The volume of distribution of verapamil was increased, whereas the blood clearance had not changed; the lignocaine infusion did not change the hepatic blood flow, as measured by indocyanine green clearance. These results show that lignocaine displaces verapamil in‐vitro and in‐vivo from its plasma protein binding sites, but the ensuing pharmacokinetic changes do not lead to significant changes in free verapamil concentrations.
Biochemical Pharmacology | 1993
An Vermeulen; Frans Belpaire; Frits de Smet; Marc G. Bogaert
The influence of i.v. administration of 10 micrograms/kg recombinant human interleukin-1 beta (rhIL-1 beta), a putative mediator of inflammation, on the pharmacokinetics and metabolism of the propranolol enantiomers was studied in rats aged 3, 12 and 24 months. After oral administration of rac-propranolol to control rats of the three age groups, the plasma concentrations of (R)-propranolol were higher than those of (S)-propranolol. Administration of IL-1 beta increased the plasma concentrations of the (R)-enantiomer markedly and significantly, those of the (S)-enantiomer only to a lesser degree. For both enantiomers an important increase in plasma binding was found in the IL-1 beta-treated rats, which was linked to the increase in alpha 1-acid glycoprotein levels. The in vitro clearance, measured in 3-month-old rats using the 9000 g liver fraction, was for neither of the propranolol enantiomers influenced by IL-1 beta treatment, which is in keeping with the unchanged cytochrome P450 content. The enantioselective influence of IL-1 beta treatment on the pharmacokinetics of propranolol was also present in 12- and 24-month-old rats, although somewhat less pronounced in the latter group. Our results show an enantioselective influence of IL-1 beta treatment on the pharmacokinetics of propranolol in the rat, favouring the (R)-enantiomer.
Mechanisms of Ageing and Development | 1992
An Vermeulen; Frans Belpaire; Frits de Smet; M. T. Rosseel; Marc G. Bogaert
The influence of age on stereoselective pharmacokinetics and in vitro metabolism of R- and S-hexobarbital was studied in the rat. After intravenous administration of the racemate, the plasma concentrations of S-hexobarbital are markedly lower than those of R-hexobarbital. For S-hexobarbital the half-life is somewhat shorter and the volume of distribution and plasma clearance is higher than for its antipode. For both enantiomers an increase in AUC and half-life, and a decrease in clearance are observed with aging. These changes occur mainly between the 3rd and the 12th month and are slightly more pronounced for R- than for S-hexobarbital, as appears from the S/R ratios. The volume of distribution shows no changes with aging. In vitro disappearance rate in 3-month-old rats is significantly higher for S- than for R-hexobarbital. There is for both enantiomers an increase in disappearance rate in 12-month-old rats as compared to younger or older rats, but this is significant only for the R-enantiomer. There are pronounced differences in the kinetics and metabolism of both hexobarbital enantiomers; changes with aging occur, but are only slightly and not always significantly more important for R- than for S-hexobarbital.
Journal of Pharmacy and Pharmacology | 1991
An Vermeulen; Frans Belpaire; Frits de Smet; Marcus Bogaert
animals were killed by decapitation. The brain was quickly removed from the skull and placed in ice-cold 0.32 M sucrose. Bilateral striata were dissected out and homogenized in ice-cold 0.4 M perchloric acid containing ethylhomocholine iodide as internal standard. ACh was extracted by the method of Hanin et a1 (1972) and estimated by HPLC (Potter et al 1983; Eva et al 1984). The results are expressed as percent of control. Statistical analysis was done using a paired t-test.
Life Sciences | 1984
Norbert Fraeyman; Frits de Smet; Eric Van De Velde; E Moerman; AndréF. De Schaepdryver
The murine C1300 neuroblastoma tumor was found to secrete dopamine, noradrenaline and dopamine B-hydroxylase into the circulation of tumor-bearing A/J mice. The plasma levels of dopamine, noradrenaline and dopamine B-hydroxylase increased with the size of the tumor, and the increase in noradrenaline paralleled the increase in dopamine B-hydroxylase (r = 0.86). The vesicular storage of dopamine and noradrenaline in the tumor was evidenced by a decrease of the tissue content of dopamine and noradrenaline 24 hours after the administration of reserpine (5 micrograms/g) respectively to 17.6% and 7.8% of control values. A similar observation could be made for the levels of dopamine and noradrenaline in the plasma of reserpinized C1300 mice. The total activity of dopamine B-hydroxylase in the tumor and in plasma was unaffected by the reserpine treatment. Chronic administration of 6-hydroxydopamine (100 micrograms/g for 8 days) had no effect on the tissue contents of dopamine, noradrenaline or dopamine B-hydroxylase. The release of catecholamines and dopamine B-hydroxylase from the C1300 neuroblastoma was studied in vitro on superfused tumor slices. Stimulation of these slices with 56 mM KC1 or with 5.10(-5) M tyramine failed to induce the release of endogenous dopamine, noradrenaline or dopamine B-hydroxylase above the basal outflow levels. These results are suggestive for a non-exocytotic release of catecholamines and dopamine B-hydroxylase from the neuroblastoma tumor.
Chirality | 1992
An Vermeulen; Frans Belpaire; E Moerman; Frits de Smet; Marc G. Bogaert
The Journals of Gerontology | 1993
An Vermeulen; Frans Belpaire; Frits de Smet; Isabelle Vercruysse; Marc G. Bogaert
Hybridoma | 1987
Norbert Fraeyman; Frits de Smet; Eric Van De Velde